➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
AstraZeneca
Dow
Colorcon
McKinsey

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Patent: 8,663,945

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,663,945
Title:Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
Inventor(s): Pla; Itzcoatl A. (Worcester, MA), Matuck; Joseph C. (Worcester, MA), Fann; John C. (Shrewsbury, MA), Schulz; Christof (Ayer, MA), Roy; Nicole A. (Worcester, MA), Bruton; David F. (Enfield, CT), McIntire; James (Castro Valley, CA), Yu-Hsiang; David Chang (Solana Beach, CA), Seewoester; Thomas (Simi Valley, CA)
Assignee: AbbVie Inc (North Chicago, IL)
Application Number:13/308,075
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,663,945
Patent Claims:see list of patent claims

Details for Patent 8,663,945

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie Inc (North Chicago, IL) 2026-09-13 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial AbbVie Inc (North Chicago, IL) 2026-09-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,663,945

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2008033517   Start Trial
United States of America 10119118   Start Trial
United States of America 2008227136   Start Trial
United States of America 2012077213   Start Trial
United States of America 2014134674   Start Trial
United States of America 2014134675   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Harvard Business School
Merck
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.